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Abstract
Background: Xue-Fu-Zhu-Yu decoction (XFZYD), Tian-Ma-Gou-Teng-Yin (TMGTY) and Wen-Dan decoction (WDD)
are Chinese herbal formulas used to treat hypertension and cardiovascular diseases in traditional Chinese medicine
(TCM). The goal of our study is to determine if XFZYD, TMGTY or WDD treatment ameliorated myocardial fibrosis in
spontaneously hypertensive rats (SHRs) and to identify the mechanisms underlying any beneficial effects observed
during the courses of the investigation.
Methods: Forty-five 12-week-old male spontaneously hypertensive rats and five age-matched male Wistar-Kyoto
control rats were studied for 16 weeks. Each day 6 g∙kg−1 or 12 g∙kg−1 of XFZYD, TMGTY or WDD was orally
administered at the indicated dose, and the systolic blood pressure (SBP) of all rats was measured using the tail-cuff
method. Collagen levels were measured via hydroxyproline content assays and histological examination.
Transforming growth factor beta-1 (TGF-β1) protein levels were determined via immunhistochemical and Western
blot analysis. TGF-β1 mRNA levels were assessed using real-time reverse transcription polymerase chain reaction.
Results: Systolic blood pressure was unaffected, but collagen and TGF-β1 levels in SHRs treated with captopril and
XFZYD (12 g∙kg−1) were significantly reduced when compared with untreated control SHRs. Administration of
12 g∙kg−1 XFZYD increased myocardial cell protection and decreased TGF-β1 mRNA and protein expression when
compared with the other SHR treatment groups.
Conclusions: XFZYD treatment demonstrated a superior ability to reverse myocardial fibrosis when compared with
WDD or TMGTY treatment in SHRs. XFZYD also decreased TGF-β1 mRNA and protein expression, suggesting that
the TGF-β1 signaling pathway plays a role in the therapeutic effects of XFZYD treatment.
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Background
Hypertension is one of the most common diseases
afflicting humans worldwide. It is a major risk factor for
stroke, myocardial infarction, vascular disease and
chronic kidney disease. Hypertension may contribute to
heart failure in as many as 50 to 60 % of patients. It con-
tributes to 50 % of ischemic strokes and increases the
risk of hemorrhagic stroke. Hypertension is the primary
cause for myocardial fibrosis, and contributes to the
pathophysiology of cardiac damage [1, 2]. Hypertension
causes a sustained increase in cardiac pressure overload,
triggering excessive proliferation and the accumulation
of interstitial and perivascular collagen fibers that leads
to myocardial fibrosis [3]. Myocardial fibrosis is an inte-
gral component of chronic heart disease [4], and it is in-
creasingly thought to have a key role in disease progression
as well [5]. Unfortunately, no specific therapies capable of
halting or reversing myocardial fibrosis are currently avail-
able. Therefore, myocardial fibrosis prevention and treat-
ment is a subject of great clinical value and public health
interest.
Transforming growth factor β1 (TGF-β1) is a key regula-
tory factor involved in the proliferation and differentiation
of fibroblasts [6]. Recent pharmacological studies targeting
TGF-β1 have reported progress in the development of
myocardial fibrosis treatments [7], but the clinical efficacy
of these treatments has yet to be established.
Traditional Chinese medicine (TCM) employs mixtures
of multiple herbs to treat patients. These mixtures are re-
ferred to as formulas or “Fufang”. It is currently thought
that the therapeutic effects that have been demonstrated
for many specific TCM therapies are mediated by multiple
ingredients. Pharmacologically active ingredients have
been demonstrated to be present in several of these
formulas, and some of these formulas have been reported
to be therapeutically effective against multiple diseases,
including tumors, inflammatory conditions and cardiac
diseases [8].
Spontaneously hypertensive rat (SHR) is a well-
established model for studying the mechanisms of
hypertrophy and heart failure associated with genetic
hypertension. SHR is often used as a model of human
essential hypertension-induced myocardial fibrosis [9].
The SHR develops hypertension at 2 to 6 weeks,
followed by progressive myocardial fibrosis, cardiac
hypertrophy, and eventual heart failure [10, 11]. Typ-
ical symptoms of myocardial fibrosis include left ven-
tricular hypertrophy (LVH) and age-related collagen
increase [12]. Several groups reported myocardial col-
lagen concentration and elevated collagen synthesis in
SHR when compared with WKY rats of similar age
[13, 14]. The myocardial fibrosis and hypertrophy in
SHR can be prevented using specific antihypertensive
agents [15].
Numerous studies published in the Chinese medical
literature have reported the successful treatment of
symptoms related to high blood pressure, such as head-
aches and dizziness, using the herbal formulas Xue-Fu-
Zhu-Yu decoction (XFZYD), Tian-Ma-Gou-Teng-Yin
(TMGTY) and Wen-Dan decoction (WDD) [16, 17].
Previous studies showed that the three Chinese formulas
have significant effects on a variety of hypertension
caused cardiovascular diseases. For example, TMGTY
can counteract myocardial fibrosis in SHR by reducing
LVI and collagen content [18]. Otherwise, the effect of
TMGTY on arterial pressure was through an action of
TMGTY on sympathetic vasomotor activity [19].
XFZYD improves endothelial function and the state be-
fore hypertensive thrombosis in the vessels of the SHRs
with hypertension and reduces the formation of myocar-
dial collagenIand III [20]. XFZYD could also improve
the ischemic necrosis and promoting the angiogenesis
[21]. WDD effectively regulates the lipid metabolism,
prevent and treat the hyperlipidemia induced diseases in
SHR [22]. Therefore, we assume that three Chinese
formulas have effect on reversion of hypertensive myo-
cardial fibrosis in SHR. However, the underlying mecha-
nisms of action and therapeutic effects of treatment with
these herbal formulas remain unclear.
The present study aimed to investigate whether XFZYD,
TMGTY or WDD were capable of reversing myocardial
fibrosis in SHR and to elucidate the mechanisms under-
lying any therapeutic effects found.
Methods
Drug preparation
Traditional Chinese herb granules manufactured by
Guangdong EFONG Pharmaceutical Co. Ltd. (Guangzhou,
China) were purchased from the pharmacy of Southern
Hospital. Captopril tablets (12.5 mg) were purchased from
Bristol-Myers Squibb Co. Ltd. (Shanghai, China; Lot num-
ber: 1209031). The components comprising the TMGTY,
WDD and XFZYD formulas are listed in Table 1, and are
based on established quality control procedures [8, 19, 23].
After preparation, the herbal mixtures were freeze-dried.
Prior to use, each 2 g of dry herbal mixture was resus-
pended in 1 ml distilled water.
Animal studies
Forty-five 12-wk-old male SHRs (280 – 320 g) and five
age-matched male Wistar-Kyoto (WKY) rats (285–310 g)
were purchased from VITAL RIVER Co. Ltd. (Beijing,
China; certificate number, SCXK2012-001). SHRs were se-
lected based on total hypertension and established myo-
cardial fibrosis. The WKY rats were used as controls. All
rats were maintained in plastic cages with soft bedding
under a 12/12 h light–dark cycle. The rats received stand-
ard care and had free access to a standard diet and
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drinking water. The protocol of this study was reviewed
and approved by the Animal Review Board of Southern
Medical University (Guangzhou, China). The research was
conducted under the Animal [Scientific Procedures] Act
of 1986 and the institutional guidelines of Southern
Medical University for the care and use of animals.
The SHRs were randomized into nine groups with five
rats in each group. The group 1 rats were treated with
distilled water and served as the SHR no-treatment
control group. Groups 2 and 3 were treated with 6 g∙kg−1
and 12 g∙kg−1 TMGTY, respectively. Groups 4 and 5 were
treated with 6 g∙kg−1 and 12 g∙kg−1 WDD, respectively.
Groups 6 and 7 were treated with 6 g∙kg−1 and 12 g∙kg−1
XFZYD, respectively. Groups 8 and 9 were treated with
30 mg∙kg−1 and 60 mg∙kg−1 captopril, respectively, and
were used as the positive treatment control group. Each
SHR was given daily oral administration of the appropriate
designated drug. The WKY control rats were also treated
with distilled water as similar with the group 1 rats for the
blank control. All the rats were fed under Specific
Pathogen-Free (SPF) conditions, with fresh, sterilized
food, vegetables and water that were changed each day.
Bedding was replaced once every two days. Environmental
noise was less than 60 dB, temperature was maintained
between 23 and 26 °C and humidity was maintained be-
tween 40 and 70 %.
The total treatment course was 16 weeks. Rat body
weight was monitored each wk and systolic blood pres-
sure was measured before and after each experiment. All
rats survived the study, and no significant abnormalities
were observed. After the final treatment, rats were anes-
thetized using 350 mg/kg of 10 % chloral hydrate and
then euthanized using cervical dislocation. The heart
was quickly removed from each euthanized rat, washed
with cold normal saline and then dried with filter paper.
One-hundred mg of the left ventricle was removed and
stored at −70 °C for further analysis. The remainder of
the left ventricle was fixed in 10 % formalin for
histology.
Systolic blood pressure measurements
Rats were housed in a 37 °C chamber for 10 min for
indirect systolic blood pressure measurements, then
transferred to a standard blood pressure measurement
apparatus that included a heating pad, acrylic restrainer,
tail cuff and pulse sensor (NarcoBiosystems, Houston,
TX, USA). The tail cuff was connected to a cylinder of
compressed air via inlet and outlet valves that allowed
steady inflation and deflation of the cuff. Tail cuff pres-
sure was continuously recorded using a solid-state pres-
sure sensor (Sensym, Honeywell Sensing & Control, Inc.,
Morristown, NJ, USA). Pulse and pressure sensor signals
were amplified and then digitized with an analogy-digital
board (DT16EZ, Data Translation, Inc., Marlboro, MA,
USA) connected to a desktop computer. Labtech Note-
book Pro (Laboratory Technology Corp., Wilmington,
MA, USA) was used to control and display the proced-
ure online. Inflation and deflation scores and the com-
pression interval were recorded for each rat [24].
Hydroxyproline content assay
The chloramine T assay was used to quantify hydroxy-
proline (HYP) in the tissues collected from the rats in






Gastrodia elata Blume Root 9 407233 T
Uncaria rhynchophylla (Miq.)
Miq. ExHavil.
Hook 12 404145 T
Reynoutria multiflora (Thunb.)
Moldenke
Aerial part 9 404203 T
Haliotis diversicolor Reeve Conch 18 311190 T
Eucommia ulmoides Oliv. Cortex 9 407270 T
Scutellaria baicalensis Georgi Root 9 409032 T
Gardenia jasminoides J.Ellis Fruit 9 407018 T
Leonurus japonicas Houtt. Aerial part 9 409112 T
Viscum coloratum (Kom.) Nakai Stem 9 408443 T
Achyranthes bidentata Blume Root 12 409081 T
Poria cocos (Schw.) Wolf Sclerotium 9 406029 T
Wen-Dan decoction (WDD)
Pinellia ternata (Thunb.) Makino Tuber 9 408101 T
Citrus × aurantium L. Young fruit 12 401084 T





Stem 9 407209 T
Glycyrrhiz auralensis Fisch. Rhizome 5 408447 T
Poria cocos (Schw.) Wolf Sclerotium 5 408407 T
Xue-Fu-Zhu-Yu decoction
(XFZYD)
Angelica sinensis (Oliv.) Diels Root 9 410141 T
Bupleurum chinense DC. Root 3 407027 T
Carthamus tinctorius L. Flower 9 408165 T
Citrus aurantium L. Fruit 6 403011 T
Cyathula officinalis Kuan Root 9 409101 T
Glycyrrhiza glabra L. Root 3 408447 T
Ligusticum striatum DC. Root 5 410141 T
Paeonia lactiflora Pall. Root 6 407380 T
Platycodon grandiflorus (Jacq.)
A. DC.
Root 5 408059 T
Prunus persica (L.) Batsch. Seed 12 406423 T
Rehmannia glutinosa (Gaertn.) DC. Root 9 403409 T
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this study [25]. The apex of the left ventricle of each rat
was defatted and lysed. Next, the sample was centrifuged
at 4000 rpm for 10 min. After centrifugation, the super-
natant was mixed with fresh chloramine T for 10 min,
followed by mixture with Ehrlich’s reagent at 75 °C for
20 min. Samples were then cooled, and the optical dens-
ity of each sample was read at 560 nm with a microplate
reader (iMark, Bio-Rad laboratories, USA). Prior to
measuring each sample, the microplate reader was ad-
justed using a “blank” sample that was prepared using
the same procedure used to prepare the experimental
samples, but without any cardiac tissue in the reaction
mixture. HYP concentration, expressed as micrograms
per milligram of dry heart weight, was then calculated as
previously described [26].
Histological examination
The remaining ventricular tissue not used in the hy-
droxyproline content assay was immediately fixed in
10 % formalin, embedded in paraffin, sliced into 5 μm
sections and then heated for 2 h in a 65 °C incubator.
These sections were stained using the Masson trichrome
method to examine myocardial interstitial fibrosis [27].
Each section was photographed at 400 x magnification
using a light microscope (CX31, Olympus, Tokyo,
Japan). All images were analyzed using Image-pro Plus
6.0 software (Media Cybernetics, Bethesda, MD, USA).
The percentage of collagen present in each micro-
scopic field represented the myocardial interstitial colla-
gen content. The accumulation of collagen content in
the interstitial spaces of the left ventricle were assessed
using polarized light microscopy and analyzed using
Image-pro Plus 6.0 software.
Immunohistochemical analysis of TGF-β1 expression
The middle ring of the left ventricle was fixed in 10 % neu-
tral formalin for 24 h, embedded in paraffin and cut into
4 μm sections. Each section was incubated at 4 °C over-
night with anti-TGF-β1 antibody (1:1000, Proteintech Co.,
Chicago, IL, USA) and at 37 °C for 30 min with Mo/Rb
type I polymer (Genecompany, Guangzhou, China). The
streptavidin-biotin-peroxidase complex technique (Histos-
tain Plus Kit, cat. No. 85–8943; Zymed, Life Technologies,
Grand Island, NY, USA) was used for immunohistochemi-
cal visualization of antibody-bound sections. Sections were
observed at 400 x magnification, and TGF-β1 staining in-
tensity was analyzed using Image-pro Plus 6.0 software.
Twenty-five random fields per section were analyzed and
combined to obtain a final value for each section.
TGF-β1 mRNA expression measurement
TGF-β1 mRNA expression was determined using real-
time reverse transcription polymerase chain reaction
(RT-PCR). Total RNA was extracted from tissues using
Trizol (Sigma, St Louis, MO, USA). RNA yields and pur-
ity were assessed by spectrophotometric analysis (Bio-
Photometer plus, Eppendorf, Germany). Total RNA
(1 μg/μl) transcription was performed using an in vitro
transcription Kit (PrimeScript RT reagent Kit Perfect
Real Time, TaKaRa, Japan). RT-PCR reactions were per-
formed with 20 μl reactions that consisted of 10 μl 2X
SYBR Premix ExTaq, 0.4 μl PCR Forward primer
(10 μM), 0.4 μl PCR reverse primer (10 μM), 2 μl cDNA,
0.4 μl ROX Reference Dye II and 6.8 μl double-distilled
water. PCR was conducted with an initial denaturation
step of 95 °C for 30 s, followed by 40 cycles of denatur-
ation at 95 °C for 5 s and 60 °C annealing for 34 s. All
RT-PCR reactions were performed in triplicate for each
sample. The primer sequences were as follows:
TGF-β1
Forward: 5’ - CATTGCTGTCCCGTGCAGA - 3’
Reverse: 5’ - AGGTAACGCCAGGAATTGTTGCTA - 3’
β-actin
Forward: 5’ - TGACGTTGACATCCGTAAAGACC - 3’
Reverse: 5’ - GTGCTAGGAGCCAGGGCAGTAA - 3’
RT-PCR and data analysis were carried out using ABI
7500 Software 2.0.3 (Life Technologies). Values obtained
for TGF-β1 were normalized against values obtained for
β-actin, and the results were expressed as relative
integrated intensity.
Western blot analysis of TGF-β1
Heart tissue was homogenized in ice-cold loading buffer
(pH 6.8). Total protein was extracted using RIPA Lysis
Buffer (Fu De Biological Technology, Hangzhou, China).
The protein was separated using a 12 % SDS-
polyacrylamide gel in electrophoresis sample buffer and
then transferred to PVDF membranes. After blocking
membranes for 1.5 h with 5 % bovine serum albumin
(BSA) in tris-buffered saline containing 0.1 % Tween-20
at pH 7.6 (TBST), the membranes were probed over-
night at 4 °C with antibodies against TGF-β1 (1:1500,
product number: ab92486, Epitomics, Burlingame,
California, USA and Abcam, Cambridge, UK). After
the overnight primary antibody incubation, the mem-
branes were washed with TBST, once for 15 min and
then an additional three times for 5 min each. After
washing, the membranes were incubated with goat
anti-rabbit horseradish peroxidase-conjugated second-
ary antibody (1:6000, product number: #7074, Cell
Signaling Technology, Danvers, MA, USA) for 1 h at
room temperature and then washed three times with
TBST for a total of 30 min. Antibody-antigen com-
plexes were visualized using enhanced chemilumines-
cence (Millipore, USA). Images were scanned and the
results were quantified using Image-pro Plus 6.0
software.
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Statistical analysis
All data were presented as means ± standard deviation
(SD). Multiple comparisons were performed using
one-way ANOVA (p < 0.05) followed by Dunnett’s
post-hoc t-test. All statistical analyses were performed
using SPSS 13.0 software (SPSS Inc. Chicago, IL,
USA).
Results
Effects of TCM on systolic blood pressure and body weight
Data obtained during this study were consistent with
data reported by previous studies, and indicated that the
systolic blood pressure of control SHRs was much
higher than that of WKY rats (Table 2, p = 0.005). Com-
parisons among the SHRs treated with WDD, XFZYD,
TMGTY and captopril revealed that captopril treat-
ment alone significantly reduced systolic blood
pressure (p = 0.032). None of the other treatments
demonstrated any anti-hypertensive effect (p = 0.085,
WDD; p = 0.075, XFZYD; p = 0.103, TMGTY).
Effect of TCM on myocardial HYP content
Myocardial HYP content levels are illustrated in Fig. 1.
TMGTY, WDD, XFZYD and captopril treatment all
significantly reduced the left ventricular HYP content
of SHRs. The strongest effect was seen after captopril
(p < 0.001, F = 94.431, df = 17, low-dose group; p =
0.003, F = 110.054, df = 17, high-dose group) and
XFZYD (p < 0.001, low- and high-dose groups) treat-
ment. High dose treatment groups exhibited a
stronger HYP reduction than the low dose treatment
groups.
Effect of TCM on myocardial collagen
Red or deep red normal muscle fibers and blue myocardial
interstitial collagen fibers were observed during micro-
scopic examination of Masson trichrome stained tissues
(Fig. 2). Generally, less collagen accumulation was seen in
the myocardia of WKY tissues when compared with tis-
sues from the SHR control group (p = 0.041; F = 74.927,
df = 17; Fig. 2). After treatment, collagen levels were sig-
nificantly reduced in all treatment groups. Notably,
less collagen was deposited in the SHR groups
treated with the TCM formulas when compared with
the collagen levels of the control SHR group, and
both XFZYD (12 g∙kg−1, p = 0.018) and captopril
(60 mg∙kg−1, p = 0.007) significantly reduced the
post-treatment myocardial collagen levels. The ob-
served reduction in myocardial collagen was not sta-
tistically significant after treatment with TMGTY
(12 g∙kg−1, p = 0.064) or WDD (12 g∙kg−1, p = 0.092).
Effect of TCM on myocardial TGF-β1
TGF-β1 expression in the myocardial interstitium of
SHR controls was significantly increased when com-
pared with the myocardial interstitium of WKY
control rats (p = 0.039; F = 73.108, df = 17; Fig. 3).
Immunohistochemistry revealed that the captopril
(60 mg∙kg−1, p= 0.021) and XFZYD (12 g∙kg−1, p= 0.034)
treated groups exhibited significantly reduced brown granule
deposits, suggesting that TGF-β1 expression was reduced in
these groups when compared with the control SHR group
(Table 3). The concentrations of brown granule deposits
were not significantly different between the TMGTY
(12 g∙kg−1, p= 0.071) and WDD (12 g∙kg−1, p= 0.078) treat-
ment groups.
TGF-β1 mRNA expression in SHR and WKY
TGF-β1 mRNA expression was increased in the left ventri-
cles of control SHRs when compared with WKYcontrol rats
(p= 0.007; F = 152.538, df = 17, low-dose group; F = 137.812,
df = 17, high-dose group; Fig. 4). Treatment with captopril
(30 mg∙kg−1, p= 0.025; 60 mg∙kg−1, p= 0.009) and XFZYD
(12 g∙kg−1, p= 0.031) significantly reduced TGF-β1 mRNA
expression in a dose-dependent manner. In contrast, neither
TMGTY (6 g∙kg−1, p= 0.095; 12 g∙kg−1, p= 0.076) nor WDD
(6 g∙kg−1, p = 0.101; 12 g∙kg−1, p= 0.078) treatment had any
effect on TGF-β1 mRNA expression.
Table 2 Effects of TCM on systolic blood pressure and body weight
SHRs
WKY Control TMGTY WDD XFZYD CAPTOPRIL
6 g∙kg−1 12 g∙kg−1 6 g∙kg−1 12 g∙kg−1 6 g∙kg−1 12 g∙kg−1 30 mg∙kg−1 60 mg∙kg−1
Systolic blood pressure (mmHg)
Before 123 ± 13 177 ± 8** 173 ± 13 176 ± 9 175 ± 11 179 ± 7 172 ± 14 170 ± 16 177 ± 13 178 ± 11
After 128 ± 11 188 ± 6** 179 ± 8 178 ± 6 177 ± 7 180 ± 9 170 ± 12 168 ± 5 161 ± 10* *** 153 ± 9* ***
Body weight (g)
Before 299 ± 7 310 ± 5 305 ± 9 303 ± 6 302 ± 7 306 ± 7 294 ± 11 298 ± 8 305 ± 7 302 ± 10
After 361 ± 12 363 ± 4 345 ± 10 351 ± 11 342 ± 13 336 ± 5 332 ± 10 330 ± 9 330 ± 8 329 ± 14
**p < 0.01 compared to the WKY rats, ***p < 0.05 compared to the SHR control
*p < 0.05 compared to the corresponding data before the experiment
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TGF-β1 protein expression in SHR and WKY
TGF-β1 protein expression differed significantly be-
tween the control SHR group and the WKY control
group (p < 0.001; F = 1408.471, df = 17; Fig. 5). Fur-
thermore, TGF-β1 protein expression in SHRs was
significantly decreased in the captopril (60 mg∙kg−1)
and XFZYD (12 g∙kg−1) treatment groups when com-
pared with the control SHR group (p < 0.001). Treat-
ment with WDD (12 g∙kg−1) also markedly reduced
TGF-β1 protein expression when compared with the
control SHR group (p = 0.036). In contrast, TMGTY
(12 g∙kg−1) treatment was not associated with a
statistically significant decrease in TGF-β1 protein ex-
pression (p = 0.064).
Discussion
Systemic hypertension is a highly prevalent chronic disease
and a significant determinant of cardiovascular morbidity
and mortality [28, 29]. It is a primary cause of myocardial
fibrosis, which in turn plays a key role in the pathophysi-
ology of hypertension-induced cardiac damage [30]. Myo-
cardial fibrosis is the excessive deposition of collagen fibers
in myocardial tissue [31], and has been closely associated
with hypertension, myocardial infarction, atherosclerosis
and diabetes. Thus, the inhibition of early hypertension
may delay ventricular remodeling and heart failure [32].
Captopril is an angiotensin-converting enzyme inhibi-
tor that is used as an anti-hypertensive agent. It is also
ameliorates myocardial fibrosis [33], and is used to treat
certain types of congestive heart failure [34]. In this
study, we compared the efficacy of captopril with three
different Chinese herbal formulas derived from TCM for
the treatment of myocardial fibrosis in SHRs.
The baseline blood pressure measured in this study
was much higher in SHRs when compared with the
baseline blood pressure in WKY rats. WDD, XFZYD
and TMGTY treatment had no effect on the systolic
blood pressure, whereas captopril treatment significantly
reduced the systolic blood pressure measured in SHRs.
XFZYD treatment at 12 g∙kg−1 each day for 16 weeks ef-
fectively inhibited myocardial fibrosis and decreased
HYP in SHR myocardial tissue. Our results suggest that
the XFZYD induced reduction in fibrosis and HYP con-
tent was independent of blood pressure, providing a the-
oretical basis for the clinical application of XFZYD.
Cardiac hypertrophy and interstitial fibrosis are com-
mon outcomes after cardiac injury and overload [35, 36].
Fig. 1 Hydroxyproline levels in the left ventricle in SHR and WKY (n= 3)
Fig. 2 Representative micrographs of cardiac collagen in the interstitial space of the left ventricle. (n = 3) (a) WKY control, (b) SHR control, (c) SHR
with 12 g∙kg−1 TMGTY, (d) SHR with 12 g∙kg−1 WDD, (e) SHR with 12 g∙kg−1 XFZYD and (f) SHR with 60 mg∙kg−1 captopril
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TGF-β overexpression is a clear factor underlying tissue
fibrosis development in numerous human diseases. Fur-
thermore, TGF-β plays a crucial role in pathogenic pro-
cesses associated with cardiac remodeling and fibrosis
[37], and the over expression of cardiac TGF-β1 is asso-
ciated with both fibrosis and hypertrophy [38].
Using immunohistochemical, RT-PCR and Western
blot analysis, we confirmed that the expression of TGF-
β1 mRNA and protein was reduced in SHRs after
16 weeks of daily treatment with 12 g∙kg−1 XFZYD. We
conclude that XFZYD inhibited fibrosis by disrupting
the TGF-β signaling pathway. Other TCM treatments
had no significant effects.
Fig. 3 Representative micrographs of TGF-β1 protein expression in myocardial tissue. (n = 3) (a) WKY control, (b) SHR control, (c) SHR with 12 g∙kg−1
TMGTY, (d) SHR with 12 g∙kg−1 WDD, (e) SHR with 12 g∙kg−1 XFZYD and (f) SHR with 60 mg∙kg−1 captopril
Table 3 Effects of TCM on myocardial TGF-β1
Sample IOD Area(μm2) Density
WKY control 1839 ± 75 2290 ± 122 0.81 ± 0.07
SHR control 1225 ± 39 1018 ± 20 1.20 ± 0.01*
TMGTY 1306 ± 74 1179 ± 58 1.12 ± 0.12
WDD 1740 ± 46 1580 ± 85 1.11 ± 0.08
XFZYTD 921 ± 43 1009 ± 43 0.92 ± 0.09**
CAPTOPRIL 591 ± 60 708 ± 11 0.83 ± 0.07**
*p < 0.05 compared to the WKY control, **p < 0.05 compared to the SHR control
Fig. 4 TGF-β1 mRNA expression in SHR and WKY. (n = 3)
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XFZYD is a classic formula in TCM clinical for treat-
ment of heart disease, our study found that XFZYD has
the effect of reverse hypertensive myocardial fibrosis and
the mechanism may be associated with TGF-β1 signaling
pathways. So we speculate that there are some active
components in the formula of XFZYD to ameliorate
hypertensive myocardial fibrosis through TGF-β1 signal-
ing pathways. Studies show that XFZYD not only can in-
hibit myocardial fibroblasts proliferation, but also to
disturb the action of collagen secretion by myocardial fi-
broblasts [39]. Ferulic acid sodium is the main active in-
gredient in Angelica sinensis (Oliv.) Diels, the structure
contains phenolic hydroxyl, which has the function of
antioxidant and antiatherosclerosis. Ferulic acid sodium
can suppress the cardiac fibroblasts proliferation in-
duced by AngII, which exhibit a dose-dependent effect,
the mechanism may be associated with lower TGF-β1
protein expression [40]. Ligustrazine is the main compo-
nent of Ligusticum striatum DC., which can block and
delay the development of myocardial fibrosis in chronic
pressure overload rats and also inhibit the myocardial fi-
broblasts induced by AngII [41]. Carthamin yellow is ex-
tracted from Carthamus tinctorius L., which can inhibit
AngII and ACE and also play a good role in cardiovascu-
lar protection [42]. Amygdalin in Prunus persica (L.)
Batsch has the effect of ameliorate hepatic fibrosis [43].
Paeoniflorin in Paeonia lactiflora Pall. has protective ef-
fect on myocardium in rats [44]. The existing research
results are consistent with our conclusion, which can
support each other. We can infer that the effective com-
ponents of XFZYD formula to ameliorate myocardial fi-
brosis through TGF-β1 signaling pathways may have
close relationship with ferulic acid sodium, ligustrazine,
carthamin yellow, amygdalin and paeoniflorin which are
extracted respectively from Angelica sinensis (Oliv.)
Diels, Ligusticum striatum DC., Carthamus tinctorius L.,
Prunus persica (L.) Batsch and Paeonia lactiflora Pall..
We plans to research the demolition party of XFZYD in
next step, and focus on the relationship between each
active ingredient and TGF-β1 signaling pathway, in order
to screen out the exact active ingredients to reverse
hypertensive myocardial fibrosis in XFZYD.
Conclusion
Among the three TCM formulas tested in this study, we
found that only XFZYD was capable of reversing myo-
cardial fibrosis. We also found that XFZYD treatment
decreased hypertension-induced cardiac fibrosis inde-
pendent of systolic blood pressure. Future clinical stud-
ies are needed to evaluate the therapeutic benefit of
XFZYD in patients with hypertension. This study dem-
onstrates that XFZYD decreases cardiac fibrosis via
TGF-β1 signaling pathway.
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